Efficacy of low-dose cytarabine and harringtonine regimen as induction in different risk stratifications of acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2016.01.016
- VernacularTitle:小剂量高三尖杉酯碱+阿糖胞苷方案诱导治疗不同危险度分层急性髓系白血病效果分析
- Author:
Danhui LI
;
Guohui LI
;
Yingmin LIANG
- Publication Type:Journal Article
- Keywords:
Low dose HA regimen;
Leukemia;
myeloid;
acute;
Risk stratification;
Molecular biology;
Cytogenetics
- From:
Journal of Leukemia & Lymphoma
2016;25(1):57-60,64
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of low-dose cytarabine and harringtonine (LD-HA) regimen in the induction therapy of acute myeloid leukemia (AML) except M3. Methods 52 AML patients who received LD-HA were analyzed retrospectively. The patients were graded according to molecular biological and cytogenetic risk degree. The clinical efficacy, toxicity of LD-HA and long-term survival followed-up were compared with those of idarubicin and cytarabine (IA) regimen in 49 patients. Results After one cycle, the overall remission (OR) rates of LD-HA group and IA group were 71.2%(37/52) [CR rate 50.0%(26/52), PR rate 21.2%(11/52)] and 53.1%(26/49) [CR rate 44.9%(22/49), PR rate 8.2%(4/49)], respectively, with no statistical significance of OR between the two groups (P= 0.068). OR rates were not statistically significant in either low-risk group or intermediate-risk group between LD-HA group and IA group (P> 0.05), but OR of high-risk group in LD-HA was much higher than that in IA group [100 % (11/11) vs 66.7 % (12/18), P<0.05]. Cardiac toxicity and bone marrow suppression in LD-HA group were much milder than those in IA group. The patients unfit for standard chemotherapy could tolerate to LD-HA regimen. Conclusions LD-HA regimen as induction for high risk AML patients can improve the OR rate, and reduce the side effects, which is beneficial for high-risk AML patients.
